Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes
| Status: | Recruiting |
|---|---|
| Conditions: | Chronic Pain, Dental |
| Therapuetic Areas: | Dental / Maxillofacial Surgery, Musculoskeletal |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 2/17/2019 |
| Start Date: | July 1, 2017 |
| End Date: | November 30, 2020 |
| Contact: | Rita Cacciato, RDH, BS |
| Email: | rita_cacciato@URMC.rochester.edu |
| Phone: | 585-275-9001 |
Opioid analgesics are the most common postoperative pain medications used among dentists in
the United States.Although these medications are highly effective in the postoperative dental
pain management, not all patients optimally benefit from this therapy. Many suffer adverse
consequences such as nausea, emesis, and psychomotor impairment, and there is a high
prevalence of opioid prescription misuse among substance abusers within the dental patient
population.
The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of
postoperative dental pain has demonstrated equivalent or superior analgesic effects compared
to opioid analgesic therapies, typically with significantly less adverse effects.However,
despite these results, dentists have encountered a high variability in the success of
non-opioid analgesic responses among the postoperative dental pain population.Thus, new
strategies for earlier recognition of analgesic responses for pain medications is fundamental
in the field of dentistry. Therefore, this study will evaluate the clinical utility of
pharmacogenomic testing in acute postoperative dental pain management among healthy adults
who undergo extraction of impacted mandibular third molar.
the United States.Although these medications are highly effective in the postoperative dental
pain management, not all patients optimally benefit from this therapy. Many suffer adverse
consequences such as nausea, emesis, and psychomotor impairment, and there is a high
prevalence of opioid prescription misuse among substance abusers within the dental patient
population.
The use of non-opioid analgesics including ibuprofen and acetaminophen in the management of
postoperative dental pain has demonstrated equivalent or superior analgesic effects compared
to opioid analgesic therapies, typically with significantly less adverse effects.However,
despite these results, dentists have encountered a high variability in the success of
non-opioid analgesic responses among the postoperative dental pain population.Thus, new
strategies for earlier recognition of analgesic responses for pain medications is fundamental
in the field of dentistry. Therefore, this study will evaluate the clinical utility of
pharmacogenomic testing in acute postoperative dental pain management among healthy adults
who undergo extraction of impacted mandibular third molar.
To date, the use of pharmacogenomic methods in medicine has broadened our understanding of
the important role of genes and different phenotypes/genotypes that make each individual
unique in pain responses, including drug biotransformation, transportation, and drug-related
side effects to name a few.Thus, recognizing the genetic profile of each individual prior to
the prescription of pain medication for postoperative dental pain management will be
essential to provide a more effective and safer pain therapy.Additionally, we suggest that
80% of the individuals in the general population exhibit a genetic profile that influence a
normal pain response to non-opioid pain therapies. Hence we postulate that the integration of
a pharmacogenomic testing to guide the prescription of ibuprofen and acetaminophen, not only,
could lead to improved clinical postoperative dental pain outcomes, but also, significantly
reduce opioid analgesics prescriptions by dentists.
the important role of genes and different phenotypes/genotypes that make each individual
unique in pain responses, including drug biotransformation, transportation, and drug-related
side effects to name a few.Thus, recognizing the genetic profile of each individual prior to
the prescription of pain medication for postoperative dental pain management will be
essential to provide a more effective and safer pain therapy.Additionally, we suggest that
80% of the individuals in the general population exhibit a genetic profile that influence a
normal pain response to non-opioid pain therapies. Hence we postulate that the integration of
a pharmacogenomic testing to guide the prescription of ibuprofen and acetaminophen, not only,
could lead to improved clinical postoperative dental pain outcomes, but also, significantly
reduce opioid analgesics prescriptions by dentists.
Inclusion Criteria:
- Patients who are able to read, comprehend, and sign the consent form, and willing to
stay in the study unit for up to 12 hours.
- Patients who are reliable, cooperative, and of adequate intelligence to record the
requested information on the questionnaire form(s).
- Women of childbearing potential who are not pregnant, as assessed by a urine pregnancy
quick test on the day of the procedure, prior to surgery. Women must be using a method
of birth control deemed acceptable by the investigator and continue to use this method
during the duration of dosing with study medication
- Patient who develop sufficient levels of pain (rated at 50mm or more out of a 100 mm)
on the DPIS within 6 hours post-surgical extraction.
- Patients who agree not to take analgesics other than protocol-defined rescue
analgesics during the post-operative treatment period of 6 hours.
- Patients who agree to refrain from alcohol and sedative consumption during the
post-operative period of 6 hours.
- Patients scheduled to undergo surgical removal of 3 or more impacted third molars, at
least 1 of which must be a bony mandibular impaction. In addition, the sum of the
dental impaction scores must be 9 or above, carried out by investigator.
Exclusion Criteria:
Subjects with:
- Known opioids and NSAIDs allergies (or induced asthmatic attacks)
- Known history of opioid abuse
- Recent history of gastrointestinal ulceration
- History of aspirin intolerance/cross-sensitivity
- Recent myocardial disease
- Uncontrolled hypertension
- Patients receiving anticoagulation therapy
- Uncontrolled diabetes
- Pregnant women
- Immunosuppression
- Recent history of opioid or NSAID therapies
- Subjects who do not achieve a qualifying baseline pain threshold of 50mm out of 100mm
on the visual analog DIPS within 6 hours of completion of surgery
We found this trial at
1
site
Click here to add this to my saved trials
